JP2024542523A - 神経変性障害の治療選択及び治療 - Google Patents

神経変性障害の治療選択及び治療 Download PDF

Info

Publication number
JP2024542523A
JP2024542523A JP2024530556A JP2024530556A JP2024542523A JP 2024542523 A JP2024542523 A JP 2024542523A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024530556 A JP2024530556 A JP 2024530556A JP 2024542523 A JP2024542523 A JP 2024542523A
Authority
JP
Japan
Prior art keywords
weeks
disease
gene
subject
disorder associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024530556A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542523A5 (https=
Inventor
ミスリング、クリストファー、ユー.
Original Assignee
アナベックス ライフ サイエンス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナベックス ライフ サイエンス コーポレイション filed Critical アナベックス ライフ サイエンス コーポレイション
Publication of JP2024542523A publication Critical patent/JP2024542523A/ja
Publication of JP2024542523A5 publication Critical patent/JP2024542523A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
JP2024530556A 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療 Pending JP2024542523A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163282615P 2021-11-23 2021-11-23
US63/282,615 2021-11-23
US202263393573P 2022-07-29 2022-07-29
US63/393,573 2022-07-29
PCT/US2022/050940 WO2023097029A1 (en) 2021-11-23 2022-11-23 Therapy selection and treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
JP2024542523A true JP2024542523A (ja) 2024-11-15
JP2024542523A5 JP2024542523A5 (https=) 2025-12-03

Family

ID=86540341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024530556A Pending JP2024542523A (ja) 2021-11-23 2022-11-23 神経変性障害の治療選択及び治療

Country Status (6)

Country Link
US (1) US20240417798A1 (https=)
EP (1) EP4436573A4 (https=)
JP (1) JP2024542523A (https=)
AU (1) AU2022396274A1 (https=)
CA (1) CA3237579A1 (https=)
WO (1) WO2023097029A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025054599A1 (en) * 2023-09-08 2025-03-13 Anavex Life Sciences Corp. Treatment and prevention of cerebral atrophy
WO2025117826A1 (en) * 2023-11-30 2025-06-05 Anavex Life Sciences Corp. Methods of using surrogate biomarkers in sigma-1 receptor therapy
CN117679516A (zh) * 2023-12-13 2024-03-12 广东工业大学 Ndufa7基因在制备改善和/或治疗线粒体功能障碍相关疾病的药物中的应用
WO2025231180A1 (en) * 2024-05-01 2025-11-06 Anavex Life Sciences Corp. Blarcamesine correction of eeg biomarkers in fragile x syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476103B1 (en) * 2005-10-17 2009-01-13 Penelope Anne Norman Science party kit and method
CN106501251A (zh) * 2016-12-09 2017-03-15 防城港市质量技术监督局 一种用于检测大麻油的试剂盒
WO2019089988A1 (en) * 2017-11-01 2019-05-09 Cognition Therapeutics, Inc. Isoindoline compositions and methods for treating neurodegenerative disease
AU2019269739B2 (en) * 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
US12352767B2 (en) * 2018-07-16 2025-07-08 University Of Virginia Patent Foundation Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity

Also Published As

Publication number Publication date
US20240417798A1 (en) 2024-12-19
EP4436573A4 (en) 2026-01-21
CA3237579A1 (en) 2023-06-01
WO2023097029A1 (en) 2023-06-01
EP4436573A1 (en) 2024-10-02
AU2022396274A1 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
JP2024542523A (ja) 神経変性障害の治療選択及び治療
EP2559434A2 (en) Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist
JP4993523B2 (ja) 20(s)−プロトパナキサジオールの抗うつ薬製造への使用
EP4297871A1 (en) Methods and compositions for treating agitation
JP2022514194A (ja) 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2016179097A1 (en) Methods for treating mitochondrial damage diseases
KR20180051561A (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
KR20180097581A (ko) 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 포함하는 정제
JP2025501646A (ja) Gm2ガングリオシドーシスの処置
KR102527378B1 (ko) 2'-fl을 함유하는 도파민 감소로 말미암아 발생하는 질환의 개선, 예방 또는 치료용 조성물
US20240131038A1 (en) Anti-inflammatory compositions comprising cannabidiol, delta-9-tetrahydrocannabinol and linalool
JP7744419B2 (ja) レット症候群を治療するためのプリドピジンまたはその類似体の使用
AU2023314929A1 (en) Therapy selection and treatment of neurodegenerative disorders
CN118613282A (zh) 神经退行性病症的疗法选择和治疗
WO2023192372A1 (en) Methods of treating sjögren-larssen syndrome
EP4284359A1 (en) Methods and compositions for preventing or reducing neuroinflammation
WO2025117826A1 (en) Methods of using surrogate biomarkers in sigma-1 receptor therapy
CN105748460B (zh) 一种治疗老年痴呆的药物
EP4591861A1 (en) Use of 4-tmap for treating or relieving depression
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
WO2025231180A9 (en) Blarcamesine correction of eeg biomarkers in fragile x syndrome
WO2025264845A1 (en) Use of anavex3-71 for medical treatments
WO2025054599A1 (en) Treatment and prevention of cerebral atrophy
WO2025240562A1 (en) Method of treating amyotrophic lateral sclerosis with trimetazidine
WO2026015656A1 (en) Responder selection and treatment with sigma-1 receptor therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251125